leflunomide has been researched along with Dermatitis, Atopic in 7 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Dermatitis, Atopic: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
Excerpt | Relevance | Reference |
---|---|---|
"A subgroup of atopic eczema patients requires systemic immunomodulatory treatment for long time periods." | 2.44 | Novel immunological approaches in the treatment of atopic eczema. ( Andres, C; Belloni, B; Mempel, M; Ollert, M; Ring, J, 2008) |
"Atopic dermatitis is a chronically relapsing eczematous disease of the skin." | 2.44 | Emerging treatment of atopic dermatitis. ( Hsu, CJ; Wang, LF, 2007) |
"Atopic dermatitis is a common inflammatory skin condition with increasing incidence in recent decades." | 2.43 | Recent developments in the treatment of adult atopic dermatitis. ( Barnetson, RS; Pua, VS, 2006) |
"Leflunomide is an immunomodulating and disease-modifying antirheumatic drug with anti-inflammatory and immunosuppressive activity, exhibiting an extremely long in vivo half life." | 2.43 | Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. ( Pfeiffer, C; Vitéz, L; Wozel, G, 2006) |
"Leflunomide is a pyrimidine de novo synthesis-inhibiting immunosuppressant exhibiting an extremely long in vivo half life of its active metabolite." | 1.32 | Leflunomide as a novel treatment option in severe atopic dermatitis. ( Pfeiffer, C; Schmitt, J; Wozel, G, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (85.71) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schmitt, J | 2 |
Abraham, S | 1 |
Trautmann, F | 1 |
Stephan, V | 1 |
Fölster-Holst, R | 1 |
Homey, B | 1 |
Bieber, T | 1 |
Novak, N | 1 |
Sticherling, M | 1 |
Augustin, M | 1 |
Kleinheinz, A | 1 |
Elsner, P | 1 |
Weidinger, S | 1 |
Werfel, T | 1 |
Belloni, B | 1 |
Andres, C | 1 |
Ollert, M | 1 |
Ring, J | 1 |
Mempel, M | 1 |
Wozel, G | 2 |
Pfeiffer, C | 2 |
Kagami, S | 1 |
Saeki, H | 1 |
Komine, M | 1 |
Kakinuma, T | 1 |
Tsunemi, Y | 1 |
Nakamura, K | 1 |
Sasaki, K | 1 |
Asahina, A | 1 |
Tamaki, K | 1 |
Pua, VS | 1 |
Barnetson, RS | 1 |
Vitéz, L | 1 |
Hsu, CJ | 1 |
Wang, LF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis[NCT00931242] | Phase 2 | 10 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks
Intervention | participants (Number) |
---|---|
Apremilast | 2 |
EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks
Intervention | participants (Number) |
---|---|
Apremilast | 1 |
Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12 (NCT00931242)
Timeframe: 12 weeks
Intervention | participants (Number) |
---|---|
Apremilast | 2 |
4 reviews available for leflunomide and Dermatitis, Atopic
Article | Year |
---|---|
Novel immunological approaches in the treatment of atopic eczema.
Topics: Adult; Antibodies, Monoclonal; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic | 2008 |
Recent developments in the treatment of adult atopic dermatitis.
Topics: Antibodies, Monoclonal; Calcineurin Inhibitors; Dermatitis, Atopic; Humans; Immunoglobulins, Intrave | 2006 |
Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data.
Topics: Adult; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Severity | 2006 |
Emerging treatment of atopic dermatitis.
Topics: Androstadienes; Animals; Dermatitis, Atopic; Desensitization, Immunologic; Fluticasone; Histamine H1 | 2007 |
3 other studies available for leflunomide and Dermatitis, Atopic
Article | Year |
---|---|
Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
Topics: Adult; Alitretinoin; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; Dermatitis, Atopic; Femal | 2017 |
Leflunomide as a novel treatment option in severe atopic dermatitis.
Topics: Acute Disease; Adult; Dermatitis, Atopic; Drug Administration Schedule; Humans; Immunosuppressive Ag | 2004 |
Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells.
Topics: Cell Line, Tumor; Cell Movement; Chemokine CCL26; Chemokines, CC; Culture Media, Conditioned; Dermat | 2005 |